Comments
Loading...

PTC Therapeutics Analyst Ratings

PTCTNASDAQ
Logo brought to you by Benzinga Data
Q1 2025 Earnings in 7 days from now on Tue May 6th, after the market close
Conference call scheduled in 7 days at 16:30 PM Click to view the webcast
Consensus Rating1
Overweight
Highest Price Target1
$113.00
Lowest Price Target1
$17.00
Consensus Price Target1
$55.05

PTC Therapeutics Analyst Ratings and Price Targets | NASDAQ:PTCT | Benzinga

PTC Therapeutics Inc has a consensus price target of $55.05 based on the ratings of 20 analysts. The high is $113 issued by Cantor Fitzgerald on February 3, 2025. The low is $17 issued by Citigroup on October 27, 2023. The 3 most-recent analyst ratings were released by RBC Capital, JP Morgan, and JP Morgan on April 22, 2025, March 31, 2025, and March 14, 2025, respectively. With an average price target of $72.67 between RBC Capital, JP Morgan, and JP Morgan, there's an implied 45.83% upside for PTC Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
3
1
Feb
3
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.9
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
JP Morgan
B of A Securities
Scotiabank
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for PTC Therapeutics

Buy NowGet Alert
04/22/2025Buy Now30.44%RBC Capital
Brian Abrahams48%
$65 → $65ReiteratesOutperform → OutperformGet Alert
03/31/2025Buy Now50.51%JP Morgan
Eric Joseph43%
$78 → $75MaintainsOverweightGet Alert
03/14/2025Buy Now56.53%JP Morgan
Eric Joseph43%
$72 → $78MaintainsOverweightGet Alert
03/11/2025Buy Now10.38%B of A Securities
Tazeen Ahmad54%
$41 → $55UpgradeUnderperform → NeutralGet Alert
03/07/2025Buy Now10.38%Scotiabank
Louise Chen54%
→ $55Initiates → Sector PerformGet Alert
03/07/2025Buy Now40.48%Morgan Stanley
Jeffrey Hung50%
$67 → $70Assumes → OverweightGet Alert
02/28/2025Buy Now44.49%JP Morgan
Eric Joseph43%
$74 → $72MaintainsOverweightGet Alert
02/18/2025Buy Now26.43%RBC Capital
Brian Abrahams48%
$60 → $63MaintainsOutperformGet Alert
02/12/2025Buy Now-9.69%Citigroup
David Lebowitz52%
$32 → $45MaintainsSellGet Alert
02/03/2025Buy Now126.77%Cantor Fitzgerald
Kristen Kluska68%
$76 → $113MaintainsOverweightGet Alert
01/15/2025Buy Now52.52%Cantor Fitzgerald
Kristen Kluska68%
$80 → $76MaintainsOverweightGet Alert
12/13/2024Buy Now34.46%Morgan Stanley
Jeffrey Hung50%
$45 → $67UpgradeEqual-Weight → OverweightGet Alert
12/04/2024Buy Now-35.78%Citigroup
David Lebowitz52%
$26 → $32MaintainsSellGet Alert
12/04/2024Buy Now-15.71%Goldman Sachs
Paul Choi60%
$32 → $42MaintainsSellGet Alert
12/03/2024Buy Now42.48%UBS
Colin Bristow39%
$47 → $71MaintainsBuyGet Alert
12/03/2024Buy Now40.48%Baird
Joel Beatty66%
$52 → $70MaintainsOutperformGet Alert
12/03/2024Buy Now12.38%Barclays
Gena Wang50%
$45 → $56MaintainsEqual-WeightGet Alert
11/27/2024Buy Now4.35%Baird
Joel Beatty66%
$48 → $52MaintainsOutperformGet Alert
11/26/2024Buy Now36.46%Wells Fargo
Tiago Fauth43%
$56 → $68MaintainsOverweightGet Alert
11/19/2024Buy Now24.42%JP Morgan
Eric Joseph43%
$51 → $62MaintainsOverweightGet Alert
11/14/2024Buy Now-9.69%Barclays
Gena Wang50%
$43 → $45MaintainsEqual-WeightGet Alert
11/11/2024Buy Now-13.71%Barclays
Gena Wang50%
$31 → $43MaintainsEqual-WeightGet Alert
11/08/2024Buy Now-3.67%Baird
Joel Beatty66%
$44 → $48MaintainsOutperformGet Alert
10/11/2024Buy Now-9.69%Morgan Stanley
Jeffrey Hung50%
$32 → $45MaintainsEqual-WeightGet Alert
10/08/2024Buy Now-11.7%Baird
Joel Beatty66%
$44 → $44ReiteratesOutperform → OutperformGet Alert
10/04/2024Buy Now-31.77%RBC Capital
Brian Abrahams48%
$32 → $34MaintainsSector PerformGet Alert
09/20/2024Buy Now28.44%Cantor Fitzgerald
Kristen Kluska68%
$64 → $64ReiteratesOverweight → OverweightGet Alert
09/17/2024Buy Now28.44%Cantor Fitzgerald
Kristen Kluska68%
$64 → $64ReiteratesOverweight → OverweightGet Alert
09/04/2024Buy Now-11.7%Baird
Joel Beatty66%
→ $44Initiates → OutperformGet Alert
08/26/2024Buy Now-5.68%UBS
Colin Bristow39%
→ $47UpgradeNeutral → BuyGet Alert
08/21/2024Buy Now28.44%Cantor Fitzgerald
Kristen Kluska68%
$64 → $64ReiteratesOverweight → OverweightGet Alert
08/09/2024Buy Now28.44%Cantor Fitzgerald
Kristen Kluska68%
$62 → $64MaintainsOverweightGet Alert
08/09/2024Buy Now-37.79%Barclays
Gena Wang50%
$25 → $31MaintainsEqual-WeightGet Alert
07/16/2024Buy Now24.42%Cantor Fitzgerald
Kristen Kluska68%
$62 → $62ReiteratesOverweight → OverweightGet Alert
07/12/2024Buy Now-35.78%Morgan Stanley
Jeffrey Hung50%
$30 → $32MaintainsEqual-WeightGet Alert
07/01/2024Buy Now24.42%Cantor Fitzgerald
Kristen Kluska68%
$52 → $62MaintainsOverweightGet Alert
06/21/2024Buy Now-35.78%B of A Securities
Tazeen Ahmad54%
$25 → $32MaintainsUnderperformGet Alert
06/20/2024Buy Now6.36%JP Morgan
Eric Joseph43%
$53 → $53MaintainsOverweightGet Alert
05/28/2024Buy Now-35.78%Goldman Sachs
Paul Choi60%
$18 → $32MaintainsSellGet Alert
05/21/2024Buy Now-47.82%Citigroup
David Lebowitz52%
$18 → $26MaintainsSellGet Alert
05/21/2024Buy Now6.36%JP Morgan
Eric Joseph43%
$43 → $53MaintainsOverweightGet Alert
05/21/2024Buy Now-35.78%Goldman Sachs
Paul Choi60%
$18 → $32MaintainsSellGet Alert
05/20/2024Buy Now-7.69%Jefferies
Kelly Shi41%
$35 → $46MaintainsBuyGet Alert
04/29/2024Buy Now-39.8%Morgan Stanley
Jeffrey Hung50%
$28 → $30UpgradeUnderweight → Equal-WeightGet Alert
04/12/2024Buy Now-9.69%Cantor Fitzgerald
Kristen Kluska68%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/20/2024Buy Now-29.76%Jefferies
Kelly Shi41%
$33 → $35MaintainsBuyGet Alert
03/08/2024Buy Now-43.81%RBC Capital
Brian Abrahams48%
$28 → $28ReiteratesSector Perform → Sector PerformGet Alert
03/01/2024Buy Now-9.69%Cantor Fitzgerald
Kristen Kluska68%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/01/2024Buy Now-43.81%RBC Capital
Brian Abrahams48%
$22 → $28MaintainsSector PerformGet Alert
03/01/2024Buy Now-39.8%TD Cowen
Joseph Thome28%
$32 → $30MaintainsMarket PerformGet Alert
01/26/2024Buy Now-55.85%RBC Capital
Brian Abrahams48%
$27 → $22MaintainsSector PerformGet Alert
01/26/2024Buy Now-9.69%Cantor Fitzgerald
Kristen Kluska68%
$51 → $45MaintainsOverweightGet Alert
12/19/2023Buy Now-43.81%Morgan Stanley
Jeffrey Hung50%
→ $28DowngradeEqual-Weight → UnderweightGet Alert
12/18/2023Buy Now2.35%Cantor Fitzgerald
Kristen Kluska68%
$51 → $51ReiteratesOverweight → OverweightGet Alert
12/18/2023Buy Now-63.88%Goldman Sachs
Paul Choi60%
$20 → $18MaintainsSellGet Alert
11/20/2023Buy Now2.35%Cantor Fitzgerald
Kristen Kluska68%
→ $51ReiteratesOverweight → OverweightGet Alert
10/27/2023Buy Now-43.81%Morgan Stanley
Jeffrey Hung50%
$31 → $28MaintainsEqual-WeightGet Alert
10/27/2023Buy Now-49.83%Barclays
Gena Wang50%
$26 → $25MaintainsEqual-WeightGet Alert
10/27/2023Buy Now-65.88%Citigroup
David Lebovitz64%
$29 → $17DowngradeNeutral → SellGet Alert
10/06/2023Buy Now-49.83%Truist Securities
Robyn Karnauskas54%
→ $25DowngradeBuy → HoldGet Alert
09/19/2023Buy Now-9.69%Truist Securities
Barry Jonas63%
→ $45ReiteratesBuy → BuyGet Alert
09/19/2023Buy Now-53.84%B of A Securities
Tazeen Ahmad54%
$43 → $23MaintainsUnderperformGet Alert
09/18/2023Buy Now-9.69%Truist Securities
Barry Jonas63%
$60 → $45MaintainsBuyGet Alert
09/18/2023Buy Now-47.82%Barclays
Gena Wang50%
$44 → $26MaintainsEqual-WeightGet Alert
09/18/2023Buy Now-37.79%Morgan Stanley
Jeffrey Hung50%
$47 → $31MaintainsEqual-WeightGet Alert
09/18/2023Buy Now-55.85%Goldman Sachs
Paul Choi60%
$35 → $22MaintainsSellGet Alert
09/18/2023Buy Now-47.82%RBC Capital
Brian Abrahams48%
$49 → $26MaintainsSector PerformGet Alert
09/18/2023Buy Now-41.8%Citigroup
David Lebovitz64%
$55 → $29DowngradeBuy → NeutralGet Alert
09/18/2023Buy Now—Raymond James
Danielle Brill42%
—DowngradeOutperform → UnderperformGet Alert
09/15/2023Buy Now—Raymond James
Danielle Brill42%
—DowngradeOutperform → UnderperformGet Alert
08/16/2023Buy Now30.44%Truist Securities
Barry Jonas63%
→ $65ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now46.5%Cantor Fitzgerald
Kristen Kluska68%
→ $73ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now-5.68%Morgan Stanley
Jeffrey Hung50%
$47 → $47ReiteratesEqual-Weight → Equal-WeightGet Alert
08/04/2023Buy Now-11.7%Barclays
Gena Wang50%
$48 → $44MaintainsEqual-WeightGet Alert
08/04/2023Buy Now10.38%Raymond James
Danielle Brill42%
$58 → $55MaintainsOutperformGet Alert
07/21/2023Buy Now46.5%Cantor Fitzgerald
Kristen Kluska68%
→ $73ReiteratesOverweight → OverweightGet Alert
07/20/2023Buy Now-1.67%RBC Capital
Brian Abrahams48%
→ $49ReiteratesSector Perform → Sector PerformGet Alert
07/20/2023Buy Now46.5%Cantor Fitzgerald
Kristen Kluska68%
→ $73ReiteratesOverweight → OverweightGet Alert
07/20/2023Buy Now0.34%Credit Suisse
Judah Frommer66%
→ $50ReiteratesNeutral → NeutralGet Alert
07/11/2023Buy Now-5.68%Morgan Stanley
Jeffrey Hung50%
$50 → $47MaintainsEqual-WeightGet Alert
06/30/2023Buy Now46.5%Cantor Fitzgerald
Kristen Kluska68%
$75 → $73MaintainsOverweightGet Alert
05/24/2023Buy Now-15.71%B of A Securities
Tazeen Ahmad54%
→ $42MaintainsUnderperformGet Alert
05/24/2023Buy Now4.35%RBC Capital
Brian Abrahams48%
→ $52MaintainsSector PerformGet Alert
05/24/2023Buy Now0.34%Credit Suisse
Judah Frommer66%
$55 → $50MaintainsNeutralGet Alert
05/24/2023Buy Now-19.73%TD Cowen
Joseph Thome28%
$47 → $40MaintainsMarket PerformGet Alert
05/24/2023Buy Now26.43%Citigroup
David Lebovitz64%
$70 → $63MaintainsBuyGet Alert
05/24/2023Buy Now-3.67%Barclays
Gena Wang50%
$57 → $48MaintainsEqual-WeightGet Alert
05/18/2023Buy Now-13.71%B of A Securities
Tazeen Ahmad54%
$36 → $43MaintainsUnderperformGet Alert
05/18/2023Buy Now40.48%Citigroup
David Lebovitz64%
$67 → $70MaintainsBuyGet Alert
05/18/2023Buy Now14.39%Barclays
Gena Wang50%
$47 → $57MaintainsEqual-WeightGet Alert
05/18/2023Buy Now-25.75%Goldman Sachs
Paul Choi60%
$35 → $37MaintainsSellGet Alert
05/08/2023Buy Now28.44%JP Morgan
Eric Joseph43%
$57 → $64MaintainsOverweightGet Alert
05/01/2023Buy Now16.4%Raymond James
Danielle Brill42%
$55 → $58MaintainsOutperformGet Alert
04/28/2023Buy Now2.35%Credit Suisse
Judah Frommer66%
$48 → $51MaintainsNeutralGet Alert
04/28/2023Buy Now34.46%Citigroup
David Lebovitz64%
$61 → $67MaintainsBuyGet Alert
04/18/2023Buy Now30.44%Truist Securities
Barry Jonas63%
$60 → $65MaintainsBuyGet Alert
03/17/2023Buy Now-3.67%SVB Leerink
Joseph Schwartz65%
→ $48Initiates → Market PerformGet Alert
02/23/2023Buy Now10.38%Raymond James
Danielle Brill42%
$60 → $55MaintainsOutperformGet Alert
02/22/2023Buy Now-27.75%B of A Securities
Tazeen Ahmad54%
→ $36MaintainsUnderperformGet Alert
02/22/2023Buy Now32.45%Cantor Fitzgerald
Kristen Kluska68%
$68 → $66MaintainsOverweightGet Alert

FAQ

Q

What is the target price for PTC Therapeutics (PTCT) stock?

A

The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by RBC Capital on April 22, 2025. The analyst firm set a price target for $65.00 expecting PTCT to rise to within 12 months (a possible 30.44% upside). 43 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for PTC Therapeutics (PTCT)?

A

The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by RBC Capital, and PTC Therapeutics reiterated their outperform rating.

Q

When was the last upgrade for PTC Therapeutics (PTCT)?

A

The last upgrade for PTC Therapeutics Inc happened on March 11, 2025 when B of A Securities raised their price target to $55. B of A Securities previously had an underperform for PTC Therapeutics Inc.

Q

When was the last downgrade for PTC Therapeutics (PTCT)?

A

The last downgrade for PTC Therapeutics Inc happened on December 19, 2023 when Morgan Stanley changed their price target from N/A to $28 for PTC Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for PTC Therapeutics (PTCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.

Q

Is the Analyst Rating PTC Therapeutics (PTCT) correct?

A

While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a reiterated with a price target of $65.00 to $65.00. The current price PTC Therapeutics (PTCT) is trading at is $49.83, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch